Increase in CIP2A expression is associated with doxorubicin resistance
Abstract
The cancerous inhibitor of protein phosphatase 2A (CIP2A) increases the migration and metastasis of various cancer cells. Overexpression of CIP2A has been shown to increase the proliferation of MDA-MB-231 cells. We thus assessed whether CIP2A expression is associated with sensitivity to doxorubicin. MDA-MB-231 cells showed an increase in CIP2A expression after treatment with doxorubicin, while MCF-7 cells showed a decrease in CIP2A expression. The overexpression of CIP2A in MCF-7 cells overcame the inhibition of cell proliferation in response to doxorubicin treatment. CIP2A expression was not affected by wild-type or mutant p53. However, mutant p53 blocked doxorubicin-mediated CIP2A down-regulation in HCT116 cells. As a regulation mechanism of doxorubicin-mediated CIP2A expression, we showed that phosphorylated Akt was involved in the suppression of CIP2A expression.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CIP2A over-expression clinically correlates with relapse from kinase inhibitor therapies.
“CIP2A also broadly regulates cancer cell therapy responses, and its over-expression clinically correlates with relapse from kinase inhibitor therapies27–30.”
From Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A (2023) · cites this paper as [30]
CIP2A inhibition sensitizes cancer cells to a large number of cancer therapies.
“CIP2A inhibition also sensitizes cancer cells to large number of cancer therapies27,28,30.”
From Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A (2023) · cites this paper as [30]
CIP2A broadly regulates cancer cell therapy responses.
“CIP2A also broadly regulates cancer cell therapy responses, and its over-expression clinically correlates with relapse from kinase inhibitor therapies27–30.”
From Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A (2023) · cites this paper as [30]
Cites
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689 · see citing works
Regulation of Cell Death Protease Caspase-9 by Phosphorylation
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E. J., Frisch, S. M., & Reed, J. C. (1998) · Science · doi:10.1126/science.282.5392.1318 · Cited by 3,118 · see citing works
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stabilityPreprint
Sears, R. C., Nuckolls, F., Haura, E. B., Taya, Y., Tamai, K., & Nevins, J. R. (2000) · Genes & Development · doi:10.1101/gad.836800 · Cited by 1,379 · see citing works
Yeh, E., Cunningham, M., Arnold, H., Chasse, D., Monteith, T., Ivaldi, G., Hahn, W. C., Stukenberg, P. T., Shenolikar, S., Uchida, T., et al. (2004) · Nature Cell Biology · doi:10.1038/ncb1110 · Cited by 791 · see citing works
Batist, G., Tulpule, A., Sinha, B. K., Katki, A. G., Myers, C. E., & Cowan, K. H. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)66748-1 · Cited by 790 · see citing works
Aas, T., Børresen‐Dale, A., Geisler, S. B., Smith‐Sørensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., & Lønning, P. E. (1996) · Nature Medicine · doi:10.1038/nm0796-811 · Cited by 736 · see citing works
CIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677 · see citing works
Phosphorylation by Glycogen Synthase Kinase-3 Controls c-Myc Proteolysis and Subnuclear Localization
Gregory, M. A., Qi, Y., & Hann, S. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m310722200 · Cited by 476 · see citing works
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells
Knuefermann, C., Lü, Y., Liu, B., Jin, W., Liang, K., Wu, L., Schmidt, M., Mills, G. B., Mendelsohn, J. M., & Fan, Z. (2003) · Oncogene · doi:10.1038/sj.onc.1206394 · Cited by 452 · see citing works
The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells.
Fulda, S., Sieverts, H., Friesen, C., Herr, I., & Debatin, K. (1997) · PubMed · Cited by 443 · see citing works
Multiple pathways regulated by the tumor suppressor PP2A in transformation
Westermarck, J., & Hahn, W. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.001 · Cited by 344 · see citing works
Sensitization of breast cancer cells to radiation by trastuzumab.
Liang, K., Lü, Y., Jin, W., Ang, K. K., Milas, L., & Fan, Z. (2003) · PubMed · Cited by 243 · see citing works
p53 Stabilization and Transactivation by a von Hippel-Lindau Protein
Roe, J., Kim, H., Lee, S.-M., Kim, S.-T., Cho, E., & Youn, H. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.04.006 · Cited by 240 · see citing works
Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo.
Pulverer, B., Fisher, C., Vousden, K. H., Littlewood, T. D., Evan, G. I., & Woodgett, J. R. (1994) · PubMed · Cited by 228 · see citing works
CIP2A Is Associated with Human Breast Cancer Aggressivity
Côme, C., Laine, A., Chanrion, M., Edgren, H., Mattila, E., Liu, X., Jonkers, J., Ivaska, J., Isola, J., Darbon, J.-M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3283 · Cited by 221 · see citing works
MYC-Dependent Regulation and Prognostic Role of CIP2A in Gastric Cancer
Khanna, A., Böckelman, C., Hemmes, A., Junttila, M. R., Wiksten, J.-P., Lundin, M., Junnila, S., Murphy, D. J., Evan, G. I., Haglund, C., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp103 · Cited by 185 · see citing works
Mechanisms of MYC stabilization in human malignancies
Junttila, M. R., & Westermarck, J. K. (2008) · Cell Cycle · doi:10.4161/cc.7.5.5492 · Cited by 144 · see citing works
Li, W., Ge, Z., Liu, C., Liu, Z., Björkholm, M., Jia, J., & Xu, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4137 · Cited by 142 · see citing works
Fulda, S., Strauß, G., Meyer, É., & Debatin, K. (2000) · Blood · doi:10.1182/blood.v95.1.301 · Cited by 127 · see citing works
Li, X., Lü, Y., Liang, K., Liu, B., & Fan, Z. (2005) · Breast Cancer Research · doi:10.1186/bcr1259 · Cited by 101 · see citing works
Mimnaugh, E. G., Dusre, L., Atwell, J. L., & Myers, C. E. (1989) · PubMed · Cited by 97 · see citing works
Somfai-Relle, S., Suzukake, K., Vistica, B. P., & Vistica, D. T. (1984) · Biochemical Pharmacology · doi:10.1016/0006-2952(84)90245-4 · Cited by 93 · see citing works
Dunkern, T. R., Wedemeyer, I., Baumgärtner, M., Fritz, G., & Kaina, B. (2002) · DNA repair · doi:10.1016/s1568-7864(02)00185-4 · Cited by 64 · see citing works
p53 induces distinct epigenetic states at its direct target promoters
Vrba, L., Junk, D. J., Novák, P., & Futscher, B. W. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-486 · Cited by 58 · see citing works
Vikhanskaya, F., & D’Incalci, M. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910610320 · Cited by 35 · see citing works
Suvasini, R., & Somasundaram, K. (2010) · Oncogene · doi:10.1038/onc.2010.123 · Cited by 14 · see citing works
Modulation of Akt Activity by Doxorubicin in Breast Cancer Cells
Tari, A. M., & Lopez-Berestein, A. M. G. (2001) · Journal of Chemotherapy · doi:10.1179/joc.2001.13.3.334 · Cited by 8 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Ruvolo, P. P. (2016) · BBA Clinical · doi:10.1016/j.bbacli.2016.08.002 · Cited by 143 · see citing works
Laine, A., Sihto, H., Come, C., Rosenfeldt, M. T., Zwolinska, A., Niemelä, M., Khanna, A., Chan, E. K., Kähäri, V.-M., Kellokumpu-Lehtinen, P.-L., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0292 · Cited by 130 · see citing works
CIP2A is a target of bortezomib in human triple negative breast cancer cells
Tseng, L.-M., Liu, C.-Y., Chang, K.-C., Chu, P.-Y., Shiau, C.-W., & Chen, K.-F. (2012) · Breast Cancer Research · doi:10.1186/bcr3175 · Cited by 122 · see citing works
Niemelä, M., Kauko, O., Sihto, H., Mpindi, J.-P., Nicorici, D., Pernilä, P., Kallioniemi, O.-P., Joensuu, H., Hautaniemi, S., & Westermarck, J. (2012) · Oncogene · doi:10.1038/onc.2011.599 · Cited by 79 · see citing works
Clinical significance of cancerous inhibitor of protein phosphatase 2A in human cancers
Khanna, A., & Pimanda, J. E. (2016) · International Journal of Cancer · doi:10.1002/ijc.29431 · Cited by 57 · see citing works
Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A
Pavic, K., Gupta, N., Omella, J. D., Derua, R., Aakula, A., Huhtaniemi, R., Määttä, J. A., Höfflin, N., Okkeri, J., Wang, Z., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36693-9 · Cited by 36 · see citing works
“The data show that the CIP2A(1-560) residues cross-linked to B56α are located primarily in the N-terminal head domain (K18, K21, E23, E34, K40) with an additional residue at the C-terminus (K490) (Fig.”
BackgroundMethodInfluentialCIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma
Xue, Y., Wu, G., Wang, X., Zou, X., Zhang, G., Xiao, R., Yuan, Y., Long, D., Yang, J., Wu, Y., et al. (2013) · Medical Oncology · doi:10.1007/s12032-012-0406-6 · Cited by 34 · see citing works
Liu, H., Qiu, H., Song, Y., Liu, Y., Wang, H., Lu, M., Deng, M., Gu, Y., Yin, J., Luo, K., et al. (2017) · Oncogene · doi:10.1038/onc.2016.355 · Cited by 19 · see citing works
Cancerous inhibitor of protein phosphatase 2A regulates cisplatin resistance in ovarian cancer
Li, W., Zhang, H., Yang, L., & Wang, Y. (2018) · Oncology Letters · doi:10.3892/ol.2018.9653 · Cited by 9 · see citing works
- Authors
- Choi, Y. A., Park, J. S., Park, M. Y., Oh, K. S., Lee, M. S., Lim, J.-S., Kim, K. I., Kim, K.-Y., Kwon, J., Yoon, D. Y., Moon, E.-Y., & Yang, Y.
- Affiliations
- Sookmyung Women's University (KR)
- Konkuk University (KR)
- Sejong University (KR)
- Corresponding author
- Yang, Young
- Venue
- FEBS Letters
- Publisher
- Wiley
- Published
- 2011-01-15
- Volume
- 585
- Issue
- 5
- Pages
- 755-760
- ISSN
- 0014-5793 (ISSN-L)
- OpenAlex
- W2106755331
- Cited by
- 54
- References
- 27
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 4 · 2022: 1 · 2021: 2 · 2019: 2 · 2018: 6 · 2017: 5 · 2016: 6 · 2015: 7 · 2014: 5 · 2013: 4 · 2012: 9
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- FEBS Letters (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Research Foundation of Korea (NRF) (R11-2005-017-04002-0, 20100028139, 20100026182, R01-2008-000-20127-0)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Cancer Mechanisms and Therapy
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- CIP2A, doxorubicin resistance, protein phosphatase 2A inhibitor, Akt phosphorylation, p53, breast cancer cells, MDA-MB-231 cells, MCF-7 cells, HCT116 cells, cell proliferation, metastasis, chemoresistance
- MeSH terms
- Autoantigens, Breast Neoplasms, Doxorubicin, Female, Humans, Membrane Proteins, Signal Transduction, Down-Regulation, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Drug Resistance, Neoplasm, HCT116 Cells, Intracellular Signaling Peptides and Proteins, Cell Proliferation, Mutant Proteins, Proto-Oncogene Proteins c-akt
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
